Explore Our Bispecific Antibody Platform for IND-Enabling Research
This scientific poster provides an overview of the bispecific antibody discovery process using four HER-2/NKG2D bispecific antibody formats as a proof-of-concept case study. HER2 is a cell surface receptor overexpressed in certain cancers, while NKG2D plays a role in immune surveillance against tumor cells. The dual binding enables the bispecific antibody to bridge the tumor cells with immune cells, enhancing immune-mediated killing of cancer cells.
Multiple bispecific valences and geometries were sampled to ensure generation of a lead candidate with enhanced functional activity, as well as dual binding. The bispecifics were tested for efficacy, function, and safety in an end-to-end bispecific antibody discovery platform. Studies included target binding, off-target screening, effector function characterization, in vitro cytotoxicity, and in vivo efficacy models.
At Charles River, we can support your bispecific antibody development every step of the way – from discovery of binders through to preclinical safety assessment. Our comprehensive platform for the discovery and functional characterization of bispecific antibodies provides a foundation for supporting Investigational New Drug (IND) applications and paves the way for progressing novel bispecific antibodies from pre-clinical to the clinical phase of the drug discovery process.
Whatever the stage of your bispecific development project, Charles River can provide support and expertise to guide you to IND submission.
Additional Information: